MX2020003034A - Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica. - Google Patents
Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.Info
- Publication number
- MX2020003034A MX2020003034A MX2020003034A MX2020003034A MX2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- binding fragment
- medical application
- antigen binding
- application therefor
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 title abstract 3
- 101150015560 IL5 gene Proteins 0.000 title 1
- 102000000743 Interleukin-5 Human genes 0.000 abstract 3
- 108010002616 Interleukin-5 Proteins 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5409—IL-5
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan un anticuerpo IL-5, un fragmento de unión a antígeno del mismo y una aplicación médica para el mismo. La presente invención comprende un anticuerpo derivado de ratón que contiene una región CDR de anticuerpo IL-5, un anticuerpo quimérico, un anticuerpo humanizado y una composición farmacéutica que comprende dicho anticuerpo IL-5 y dicho fragmento de unión a antígeno del mismo, así como el uso de la composición farmacéutica como una droga.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710906068 | 2017-09-29 | ||
| PCT/CN2018/108240 WO2019062831A1 (zh) | 2017-09-29 | 2018-09-28 | Il-5抗体、其抗原结合片段及医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003034A true MX2020003034A (es) | 2020-07-22 |
Family
ID=65900695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003034A MX2020003034A (es) | 2017-09-29 | 2018-09-28 | Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11365247B2 (es) |
| EP (1) | EP3689906A4 (es) |
| JP (1) | JP7307720B2 (es) |
| KR (1) | KR102709785B1 (es) |
| CN (1) | CN111065651B (es) |
| AU (1) | AU2018340557B2 (es) |
| BR (1) | BR112020005766A2 (es) |
| CA (1) | CA3076941A1 (es) |
| MX (1) | MX2020003034A (es) |
| MY (1) | MY201928A (es) |
| TW (1) | TWI801425B (es) |
| WO (1) | WO2019062831A1 (es) |
| ZA (1) | ZA202001807B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3939611A4 (en) * | 2019-03-29 | 2022-12-21 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY AND USE THEREOF |
| CN117903303A (zh) * | 2020-08-20 | 2024-04-19 | 南京融捷康生物科技有限公司 | Il-5的结合分子及其应用 |
| US20250051435A1 (en) * | 2023-08-11 | 2025-02-13 | Invetx, Inc. | Anti-il-5 antibodies and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| CZ291039B6 (cs) | 1992-02-06 | 2002-12-11 | Schering Corporation | Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek |
| GB9412230D0 (en) * | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| US7399837B2 (en) | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| KR100509993B1 (ko) * | 1994-12-23 | 2006-02-28 | 스미스클라인비이참피이엘시이 | Il-5 매개된 질환의 치료에 유용한 재조합 il-5 길항제 |
| US5683892A (en) * | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| ATE346867T1 (de) | 1994-12-23 | 2006-12-15 | Smithkline Beecham Corp | Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten |
| JP2005530490A (ja) | 2002-03-29 | 2005-10-13 | シェーリング コーポレイション | インターロイキン−５に対するヒトモノクローナル抗体および方法およびこれを含む組成物 |
| US8192736B2 (en) | 2004-10-28 | 2012-06-05 | Kyowa Hakko Kirin Co., Ltd | Remedy for endometriosis |
| GB2468232B (en) | 2007-11-30 | 2012-10-24 | Glaxo Group Ltd | Antigen-bindng constructs |
| WO2009072660A1 (ja) | 2007-12-03 | 2009-06-11 | Kabushiki Kaisya Advance | 抗体作製方法 |
| KR101941514B1 (ko) | 2010-12-22 | 2019-01-23 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 개선된 반감기를 가지는 변형된 항체 |
| EP2710370A4 (en) | 2011-05-18 | 2015-01-07 | Medimmune Llc | METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS |
| RU2732032C2 (ru) | 2013-12-20 | 2020-09-10 | Дженентек, Инк. | Антитела с двойной специфичностью |
| HRP20201307T1 (hr) | 2014-09-08 | 2020-11-27 | Cephalon, Inc. | Upotreba reslizumaba za liječenje umjerene do ozbiljne eozinofilne astme |
| CN116474091A (zh) | 2015-08-24 | 2023-07-25 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 生物医药组合物 |
-
2018
- 2018-09-28 BR BR112020005766-5A patent/BR112020005766A2/pt unknown
- 2018-09-28 JP JP2020517497A patent/JP7307720B2/ja active Active
- 2018-09-28 MY MYPI2020001584A patent/MY201928A/en unknown
- 2018-09-28 US US16/651,639 patent/US11365247B2/en active Active
- 2018-09-28 AU AU2018340557A patent/AU2018340557B2/en active Active
- 2018-09-28 CA CA3076941A patent/CA3076941A1/en active Pending
- 2018-09-28 KR KR1020207010252A patent/KR102709785B1/ko active Active
- 2018-09-28 WO PCT/CN2018/108240 patent/WO2019062831A1/zh active IP Right Grant
- 2018-09-28 TW TW107134416A patent/TWI801425B/zh active
- 2018-09-28 CN CN201880058448.5A patent/CN111065651B/zh active Active
- 2018-09-28 MX MX2020003034A patent/MX2020003034A/es unknown
- 2018-09-28 EP EP18860941.6A patent/EP3689906A4/en active Pending
-
2020
- 2020-03-23 ZA ZA2020/01807A patent/ZA202001807B/en unknown
-
2022
- 2022-05-18 US US17/747,627 patent/US12258394B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3689906A1 (en) | 2020-08-05 |
| WO2019062831A1 (zh) | 2019-04-04 |
| KR20200059239A (ko) | 2020-05-28 |
| CA3076941A1 (en) | 2019-04-04 |
| US20220356239A1 (en) | 2022-11-10 |
| RU2020112984A (ru) | 2021-10-29 |
| EP3689906A4 (en) | 2021-04-07 |
| AU2018340557B2 (en) | 2025-02-27 |
| TWI801425B (zh) | 2023-05-11 |
| AU2018340557A1 (en) | 2020-04-09 |
| MY201928A (en) | 2024-03-24 |
| RU2020112984A3 (es) | 2021-11-25 |
| TW201915022A (zh) | 2019-04-16 |
| ZA202001807B (en) | 2022-09-28 |
| JP7307720B2 (ja) | 2023-07-12 |
| US11365247B2 (en) | 2022-06-21 |
| BR112020005766A2 (pt) | 2020-10-13 |
| JP2021502801A (ja) | 2021-02-04 |
| CN111065651B (zh) | 2023-07-14 |
| US20200262909A1 (en) | 2020-08-20 |
| US12258394B2 (en) | 2025-03-25 |
| CN111065651A (zh) | 2020-04-24 |
| KR102709785B1 (ko) | 2024-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
| CO2019007823A2 (es) | Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo | |
| MX2022014867A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
| MX2021005396A (es) | Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo. | |
| ZA202004701B (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| CO2020010277A2 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
| BR112018014016A2 (pt) | combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer | |
| MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
| CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
| CR20170200A (es) | Conjugados de anticuerpo-farmaco | |
| MX373245B (es) | Anticuerpos cd3 humanizados o quiméricos. | |
| BR112017001588A2 (pt) | conjugados de anticorpo/fármaco anti-cdh6 | |
| MX385456B (es) | Anticuerpos cd123 y conjugados de los mismos. | |
| BR112017007170A2 (pt) | anticorpos anti-ox40 humanizados e suas utilizações | |
| BR112017022838A2 (pt) | receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos | |
| BR112016014731A2 (pt) | Anticorpos anti-baff | |
| MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
| MX2017012615A (es) | Anticuerpo anti-notch4 humano. | |
| CO2018000652A2 (es) | Anticuerpo anti-epha4 | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| NZ729395A (en) | Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody | |
| MX2019015914A (es) | Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| MX2021003168A (es) | Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico. | |
| MX2020003034A (es) | Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica. |